Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.200
-0.010 (-0.83%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States.
It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Phio Pharmaceuticals Corp.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Robert Bitterman |
Contact Details
Address: 411 Swedeland Road, Suite 23-1080 King Of Prussia, Pennsylvania 19406 United States | |
| Phone | 610 947 0251 |
| Website | phiopharma.com |
Stock Details
| Ticker Symbol | PHIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001533040 |
| CUSIP Number | 71880W303 |
| ISIN Number | US71880W5013 |
| Employer ID | 45-3215903 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert J. Bitterman | President, Chief Executive Officer and Chairman |
| Lisa C. Carson | Chief Financial Officer, Principal Accounting Officer and Vice President of Finance and Administration |
| Linda M. Mahoney | Senior Vice President of Development |
| Dr. Jennifer Phillips Pharm.D. | Senior Vice President of Regulatory and Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2026 | 8-K | Current Report |
| Apr 8, 2026 | 424B5 | Filing |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 18, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 10, 2026 | 8-K | Current Report |
| Jan 20, 2026 | 8-K | Current Report |